Cargando…
P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia
Imatinib was the first BCR-ABL-targeted agent approved for the treatment of patients with chronic myeloid leukemia (CML) and confers significant benefit for most patients; however, a substantial number of patients are either initially refractory or develop resistance. Point mutations within the ABL...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2008
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567340/ https://www.ncbi.nlm.nih.gov/pubmed/18828913 http://dx.doi.org/10.1186/1756-8722-1-15 |